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Abstract
Background: Abnormal variations in the expression level of some commonly expressed T-cell
antigens are a feature of many T-cell malignancies.
Methods: We sought to assess the frequency of such abnormal antigen expression by flow
cytometry in peripheral blood (PB) samples from patients with mycosis fungoides (MF) and Sézary
syndrome (SS). We correlated presence of morphologically identifiable tumor cells on PB smear
with the frequency of abnormalities in the level of expression of CD3, CD4, CD7, CD8 and CD26.
We also examined the degree of stability of these abnormal findings in tumor cells over the course
of disease. The flow cytometric findings in 100 PB samples from 44 patients, including 38 who had
multiple sequential PB samples (2–8 samples each), were assessed.
Results: Abnormalities were seen in the expression level of one or more T-cell markers in 41
cases (93%) including CD3 in 34% of patients, CD4 in 54%, CD26 in 86% and CD 45 in 40% (10
cases tested). In all but 2 cases, the abnormal T-cell immunophenotype remained similar over the
course of treatment and correlated with the relative numbers of tumor cells counted on PB smear.
Conclusions: Using a standard T-cell panel, stable phenotypically aberrant T-cell populations
representing the tumor are detected in the vast majority of involved PB samples in MF/SS and can
be used to monitor response to therapy.
Introduction
Enumeration of peripheral blood (PB) leukemic cells in
mycosis fungoides (MF)/Sézary syndrome (SS) can be dif-
ficult by morphological methods. This is due to difficul-
ties in unequivocally distinguishing neoplastic cells from
reactive lymphocytes on standard Wright-Giemsa-stained
PB smears. Electron microscopic evaluation of blood sam-
ples is impractical for routine use. Therefore, most centers
have relied on flow cytometric evaluation of such speci-
mens.
Flow cytometric abnormalities in MF/SS that have been
correlated with the presence of tumor cells include in-
creased populations of CD4-positive and/or CD7-nega-
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tive T-cells. [1–3] We have recently shown that increases
in CD4-positive, CD26-negative T-cell populations are
highly associated with the presence of tumor cells in MF/
SS [4].
Another approach to flow cytometric detection of tumor
cells has been the identification of phenotypically aber-
rant populations that express different amounts of cell
surface proteins than normal T-cell populations. Such sta-
ble abnormal expression levels of pan-T cell markers is a
common feature of T cell tumors [5]. We sought to iden-
tify the frequency of such abnormalities in MF/SS in PB
and to determine whether these immunophenotypic aber-
rancies are stable over the course of treatment. We report
that alterations in expression of multiple T cell markers as
detected by flow cytometry are an easily identifiable and
stable feature of nearly all cases of MF/SS. Such immu-
nophenotypic aberrancies can be used to quantify tumor
cells from a patient over the course of the disease.
Methods
Patient samples
We screened all PB smears from patients referred to our
hospital between January 1999 and June 2002 who had a
diagnosis of cutaneous atypical lymphoid infiltrate, MF,
or SS and a had a full PB flow cytometry panel. Cases were
considered morphologically positive if they contained at
least 1% tumor cells by manual differential. We also in-
cluded subsequent involved PB samples from these pa-
tients. Most of the PB smears were reviewed by a single
hematopathologist (DJ) to ensure relatively uniform crite-
ria in counting of tumor cells. Sézary tumor cells were de-
fined as either those with markedly convoluted nuclear
contours or those that were enlarged and had prominent
nucleoli. Diagnoses were based on criteria outlined in the
updated World Health Organization classification [6]. Pa-
tients were diagnosed to have MF if PB involvement oc-
curred subsequent to patch/plaque cutaneous T-cell
lymphoma or SS if the presenting features included an
erythrodermic rash with >500/µL PB tumor cells.
All studies were carried out in accordance with the Decla-
ration of Helsinki and followed a laboratory protocol ap-
proved by our institutional review board.
Flow cytometry
We utilized a standard T-cell antigen panel to analyze the
100 PB samples from the 44 patients. 2-, 3- or 4-color flow
cytometric analysis was performed on all samples follow-
ing a standard red cell lysis method using mouse mono-
clonal antibodies directed against CD45 (clone 2D1,
peridin-chlorophyll-a-protein [PerCP]-conjugated,) as
well as various combinations of CD26 (fluorescien isothi-
ocyanate [FITC]-conjugated), CD3 (SK7, FITC or phyco-
erythrin [PE]), CD4 (SK3, PE), CD7 (4H9, FITC), CD8
(SK1, FITC or PE), CD19 (SJ25C1, FITC) and CD26
(L272, FITC). In addition, CD2 (S5.2, FITC), CD5
(L17F12, PE), and αβ T-cell receptor (T10B9, FITC or PE)
were done, in a subset of cases. All antibodies were from
BD Biosciences, San Jose, CA and analysis was performed
using FACScan or FACScaliber cytometers (BD).
For each antibody, negative staining levels were set by
comparison to an isotype-matched control. In a subset of
23 cases, cluster analysis using Paint-a-gate® software (BD)
was done to correlate the size of the different lymphocyte
populations with the phenotypically aberrant T-cell clus-
ters. Aberrant T cell populations were defined as discrete
immunophenotypic clusters (representing a tight cluster
of 0.5% or more of analyzed events) exhibiting change in
levels of expression of T-cell antigens relative to an inter-
nal immunophenotypically normal T-cell population or
relative to expected expression of T cell associated anti-
gens. As a control group for variations in T-cell markers in
non-neoplastic T-cell populations, we used the flow cy-
tometry results from 100 patients with MF or cutaneous
atypical T-cell infiltrates whose PB smears did not show
identifiable tumor cells, and 10 samples from control pa-
tients without any evidence of malignancy or chronic dis-
ease. The details of these PB cases were previously
summarized [4]. We have previously shown high levels of
correlation between the presence of an abnormal T-cell
population identified by this flow cytometry panel and
the presence of morphologically identifiable tumor cells
on examination of the smear [4].
The Kruskal-Wallis test and Spearman's rank correlation
test were used to compare the association of phenotypic
aberrancy between different markers. Statistical signifi-
cance was defined as α = 0.05.
Results
Immunophenotypic aberrancy of common T-cell markers 
is present in nearly all cases of MF/SS
In 41 of 44 MF/SS patients (93%), there was a discrete
phenotypically abnormal population(s) identified by
flow cytometric analysis that correlated with the presence
of morphologically identifiable tumor cells on PB smear.
In a group of 100 SS/MF patients with morphologically
uninvolved PB smears, flow cytometric analysis identified
a phenotypically abnormal CD4+ T-cell population in
only 2 cases. These abnormal populations, detected only
by flow cytometry, comprised 1 and 2% of total white
blood cells and were discrete CD4-dim CD26-negative T-
cell populations. Rereview of PB smears from these pa-
tients, who had typical cutaneous findings of MF, did not
identify definitive Sezary cells. The CD4/CD8 ratio was el-
evated (>4:1) in 77% of the involved PB samples, at pres-
entation, and in 74% of the followup involved PB
samples but in only 13% of the PB samples from MF/SSBMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/5
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patients without tumor cells seen on smear. No flow cyto-
metric abnormalities were detected in CD4-positive T-
cells from 10 control patients without lymphoprolifera-
tive disorders.
The overall incidence of different immunophenotypic ab-
errancies among the 44 MF/SS patients is summarized in
Table 1. We noted abnormal expression levels of CD3 by
flow cytometry in 34% of patients; tumor cells were dim-
mer for CD3 than normal T-cell levels in 11 patients,
brighter than normal for CD3 in 2 patients (Fig. 1A) and
completely negative for CD3 in 2 patients. Similarly, ab-
normal levels of CD4 expression were seen in 24 (54%)
patients (21 dimmer, 1 brighter, 2 negative) (Fig. 1B). Co-
expression of CD4 and CD8 was seen in tumor cells from
2 patients. In 17% of patients, tumor cells showed both
CD3 and CD4 aberrancies, however the magnitude of
these changes were not highly correlated when graded as
negative (0), dim (1), normal (2) or bright (3) (R value =
.23).
In a subset of cases tested, abnormalities in the dimmer
expression level of CD 45 were seen in 4 of 10 (40%) cases
(Fig. 1A). T-cell receptor-alpha/beta (TCR-α/β) expression
levels were determined in 19 cases and was 100% correlat-
ed with CD3 expression, in that dim TCR-α/β expression
in 3 cases was associated with dim CD3 and TCR-α/β was
negative in the 2 cases that showed absence of surface
CD3. CD5 expression was abnormal in 5 of 20(25%), of
tested cases (dimmer in 4, brighter in 1), by standard anal-
ysis. However, the level of CD5 expression in T-cells was
typically variable and careful cluster analysis in 5 addi-
tional cases identified discrete CD5-dim tumor cell popu-
lations.
T-cells in normal PB typically showed a continuous varia-
tion in CD7 expression level. In involved MF/SS PB sam-
ples, tumor cells were uniformly negative in 17 patients
(39%) and uniformly positive in 10 patients (23%). In
the remaining 17 patients (38%), CD7 expression in tu-
mor was variable (Fig. 1B) and was often indistinguisha-
ble from the range of expression seen in normal T-cells.
Figure 1
Sézary syndrome with multiple immunophenotypic aberrancies in tumor cells. Aberrant events representing neo-
plastic cells are painted red and normal CD4 and CD8 T-cell populations are painted green. A. Tumor cells are CD3 
bright(+)CD45 dim(+). B. They are also CD4 dim(+)CD7 bright(+) phenotype and are separable from the normal CD4(+) T-
cell population. C Tumor cell population is CD4 dim(+) CD26(-).
Table 1: Overall incidence of aberrancies in common T-cell markers in tumor cells of MF and SS.
Aberrancy CD3 CD4 CD5* CD7 CD8 CD26 CD45* TCR*
% of cases 34% 54% 25% 61% 5% 86% 40% 31%
cases tested 15/44 24/44 5/20 27/44 2/44 38/44 4/10 6/19
*Markers tested on only a subset of cases.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/5
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The T-cell activation marker CD26 was uniformly negative
in tumor cells from 36 patients (81%), uniformly positive
in 2 patients and showed variable positivity in 6. Thus, in
38 of 44 (86%) patients, CD4/CD26 and CD3/CD26 his-
tograms clearly separated the phenotypically atypical T-
cell populations (Figs. 1C and 2).
Multiple phenotypically aberrant T-cell populations in 
MF/SS
In 5 patients with long standing MF, we noted 2 discrete
phenotypically abnormal T-cell populations in PB. In 2
patients, these included a CD3-dim population (Fig. 3A);
in 2 other patients there were CD4-dim and CD4-negative
populations (Fig. 3B/3C). The remaining patient had two
discrete populations detected by CD45 and CD5 staining.
In 4 cases, cluster analysis correlated the different pheno-
typically aberrant populations with the normal-sized and
large transformed neoplastic T-cell populations seen on
PB smear. This was done by pseudocoloring the abnormal
cell cluster in the various antibody panels and correlating
the relative cell size of these clusters on the forward/side
scatter histograms (Fig. 3A/3C).
Phenotypic aberrancies in T-cells are stable over the 
course of disease
In 38 of the patients, we analyzed followup PB samples
that had tumor cells identified on smear and a phenotyp-
ically abnormal population identified by flow cytometry.
We examined from 2 to 8 different samples from these pa-
tients over the 3-year study period. In a subset of cases, we
used the Paint-a-gate software (on the forward-side scatter
and other histograms) to quantify the size of the aberrant
(tumor cell) T-cell population in comparison with the
other white blood cell types detected. As shown in Table
2, such a technique could be used to document oscilla-
tions in tumor cell number that occurred over the course
of treatment.
In 36 of 38 patients, phenotypic aberrancies in the levels
of CD3, CD4 and CD26 were stable with similar expres-
sion levels detected in all involved PB samples. In con-
trast, CD7 expression varied in the aberrant tumor cell
population in 10 of 38 (26%) cases. Fig. 4 shows a patient
with CD4-dim phenotypic aberrancy in tumor cells that
remained constant over the course of disease. In this pa-
tient, intervening treatments with Targretin, interferon,
and photopheresis had no discernible effect on overall PB
tumor cell number. However, initiation of deoxycoformy-
cin (pentostatin) therapy resulted in a decrease in the size
of the aberrant CD7-dim tumor cluster (as well as decreas-
es in the population of normal T-cells), consistent with
treatment response.
In 2 patients, there were changes in the phenotype of tu-
mor cells noted over the study period. In one case, large
cell transformation of tumor cells was associated with par-
tial loss of surface CD3. In another case with CD4-dim
Figure 2
Absence of CD26 expression is useful in isolating neoplastic T-cell populations. A. Non-neoplastic PB shows normal 
variable expression of CD26 in CD4(+) T-cells. B. The forward/side scatter histogram from a case of MF in PB. Aberrant 
events representing neoplastic cells are painted red and phenotypically normal CD4 and CD8 T-cell populations are painted 
green. C. CD4/CD26 histogram shows a discrete uniformly CD26(-) abnormal T-cell population representing tumor cells.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/5
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and CD4-negative tumor cell populations, effective treat-
ment was associated with selective loss of the CD4-nega-
tive population (data not shown).
Discussion
We examined the flow cytometry findings in involved PB
samples from 44 MF/SS patients, most of who had multi-
ple sequential involved PB samples. Using a standard T-
cell cytometry panel, we noted abnormal T-cell popula-
tions showing one or more antigen aberrancies in 93% of
patients. In 5 MF patients, we noted multiple persistent
phenotypically abnormal T-cell populations consistent
with clonal heterogeneity. We present the first report on
the stability of such abnormal immunophenotypes in the
neoplastic T cells of SS/MF, over disease course. Despite
varying treatments, immunophenotypic aberrancies not-
ed were maintained over the course of disease in 95% of
cases, excluding common variations in the level of CD7
expression. These findings support the hypothesis that
these abnormal T-cell populations represent the neoplas-
tic clone and provide strong support for the use of flow cy-
tometry in routine monitoring of treatment response.
Figure 3
Mycosis fungoides in peripheral blood with multiple aberrant T-cell populations. A. CD3 versus forward scatter 
identifies two abnormal populations, one large and one small, that are distinct from normal T cells. Examination of PB smear 
identified small (cerebriform) and large (transformed) tumor cell populations (not shown). B. Another case of MF in PB shows 
two atypical T-cell population; one CD4dim(+) (colored green) and another CD4(-) (red) distinct from the normal CD4(+) T-
cells (blue). The CD4(-) population was also negative for CD8 (data not shown). C. Forward/side scatter histograms revealed 
the CD4(-) population predominantly comprised the larger (transformed) tumor lymphocyte population that was noted on PB 
smear.
Table 2: Variations in the number of neoplastic cells versus normal white cell populations in one MF patient over the course of 
treatment.
Date of sample White blood cell 
count (× 103/µL)
Tumor cells* Normal white blood cell populations
CD4 (+) T-cells CD8 (+) T-cells NK & B-cells grans monos
7/26/00 2.8 25% 6% 1% 13% 42% 13%
9/5/00 4.2 5% 2% 4% 3% 85% 1%
9/22/00 5 10% 2% 3% 2% 79% 4%
11/11/00 5.5 16% 2% 1% 4% 76% 1%
*Tumor cells had a CD3(+)CD4(-)CD8(-) immunophenotype, allowing accurate separation from normal T-cell populations.BMC Clinical Pathology 2002, 2 http://www.biomedcentral.com/1472-6890/2/5
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Tumor-associated variation in one or several pan-T cell
antigens is a typical feature of neoplastic lymphocytes in
many T-cell malignances and has been termed antigen
"loss" or "deletion" [7]. Using immunohistochemistry on
a large bank of T-cell lymphomas, we have previously not-
ed a frequency of such antigen deletion of 18% for CD2,
26% for CD3, 30% for CD5 and 68% for CD7 [8]. Flow
cytometric analysis can allow a more sensitive assessment
of subtle variations in the levels of surface marker expres-
sion than immunohistochemistry [9]. In non-neoplastic
T-cell populations, we noted relatively narrow range of
CD3, CD4 and CD5 expression with majority of cells clus-
tering within one log intensity. In contrast, the aberrancies
noted in expression in T-cell tumor often showed 2–3 log-
fold intensity differences from the normal populations
[5,9–12].
Most routinely assessed T-cell diagnostic markers (e.g.
TCR-α/β, CD3, CD4, CD8 and CD45) are components of
the antigen receptor complex and are dynamically regulat-
ed during T-cell maturation and activation [13]. In a sub-
set of cases analyzed, we noted that surface CD3 levels
frequently correlated with levels of TCR-α/β, but that CD3
did not always correlate with variations in the levels of
surface CD4. We also found variations in MF/SS tumor
cells in the expression level of CD45, a phosphatase that
regulates TCR activation [14]. The finding of frequent var-
iations in the levels of these TCR-complex proteins in tu-
mors is intriguing and suggests abnormal regulation or
formation of the TCR complex in some tumor cells. This
could be lead to dysregulated TCR signaling effecting
growth regulation.
In previous studies, others and we have noted that MF/SS
tumor cells frequently lacked CD26, and that this finding
was helpful in identifying the tumor cell population
[4,15]. In this larger longitudinal series, we confirm these
findings and noted that tumor cells showed a consistent
pattern of CD26 loss over the course of disease. The stable
loss of expression of CD26, a T-cell activation marker, in
MF/SS suggests that this activation pathway may be non-
functional in most MF/SS tumors. CD26 is an ectoen-
zyme, which delivers a costimulatory signal in T-cells; its
expression is upregulated on T-cells in response to mi-
togenic signals and downregulated through interaction
with the insulin-like growth factor II receptor [16]. The
consequence of CD26 loss is unclear; CD26 modulates
the action of many molecules including the chemotactic
activity of some chemokine important for T-cell migration
to skin [17,18].
In contrast, we noted that CD7 expression was frequently
modulated in tumor cells over the disease course. Several
previous studies have demonstrated that CD7 loss is not a
predictable marker for detection of MF/SS cells, as its ex-
pression is variable in this tumor type [15,19]. Although
there is data to suggest that CD7-negative T-cells may rep-
resent a distinct differentiation pathway in normal and
neoplastic helper T cells,[20,21] the variable expression of
CD7 in MF/SS that we have observed suggests that this
marker may be highly modulated by tumor microenviron-
ment and/or treatment.
Identification of a stable tumor-associated immunophe-
notype in MF/SS allows tumor cell quantification to assess
response to therapy. Cluster analysis of abnormal flow cy-
Figure 4
Stability of abnormal tumor immunophenotype of sequential samples from a SS patients undergoing treat-
ment. There is stable expression of dim CD4 in the tumor cells, with CD7dim(+) and CD7bright(+) populations painted red 
and green, respectively. The histogram on the far right shows a decrease in the CD7dim(+) population in response to pento-
statin therapy. No overall decreases in tumor cell number in response to the prior Targretin, interferon or photopheresis 
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tometric immunophenotype is more reliable and easier to
compare over time than morphologic analysis, and can
detect PB involvement in a small number of cases without
easily identifiable Sezary cells [12]. Routine flow cytomet-
ric profiling is also not as technically demanding as mo-
lecular monitoring[22,23] or electron microscopy. Such a
separation of tumor from normal T-cells is also important
in assessing the effects of therapies on normal leukocytes.
In conclusion, we found that the absence of CD26 and
other aberrant surface expression of T cell-associated
markers allowed identification of a discrete, quantifiable
population in nearly all MF/SS patients with PB tumor
cells. Immunophenotypic aberrancies are maintained
consistently over the course of disease and can be used to
monitor tumor response to therapy.
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